A Prebiotic Agave Derivated Metlin & Metlos in Infant Formula

Double Blind, Randomized, Controlled Clinical Trial for Evaluate The Efficiency and Safety of a Fiber System From Agave, With Prebiotic Action, Metlin® and Metlos®, Incorporated to an Infant Formula for Term Newborn Babies

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01251783

Enrollment

600

Registered

2010-12-02

Start date

2010-02-28

Completion date

2010-10-31

Last updated

2010-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Term Babies

Keywords

term babies

Brief summary

Objectives: To evaluate the safety; efficacy; bone mineral metabolism & immunity changes of the use of Metlin & Metlos added to the Infant Formula Study Design: Randomized, double blind, clinical, controlled trial, in 600 full-term infants of 15 ± 7 days randomized to recive formula with probiotics + Metlin + Metlos; formula with probiotics + Metlin; Formula with probiotics + Metlos; formula only with probiotics or formula without probiotics and prebiotics; having a totally breast feed group as control.). Outcomes variables were frequency of stools; bowel intolerance manifestations (abdominal distension, flatulency, regurgitations, vomiting); report of dermatological problems like eczema; changes on the intestinal microbiota; lipids profile (cholesterol, triglycerides, lipoproteins associated to cholesterol); anthropomorphic profile and somatic growth ( weight gain, stature, arm mean circumference, skin folds); bone mineral metabolism (high-speed bone ultrasonography); and changes in the immunity (changes in the concentrations of salivary IgA and the frequency of respiratory events suggestive of infection)\]. Statistical analysis was made with STATA Ver. 11.0 for Mac. Safety and efficacy variables, were compared by Chi squared in the case of categorical variables or by ANOVA or Kruskall Wallis for the numeric variables. When convenient, a covariates adjustment was done by ANOVA or by multiple lineal regressions for continuous numerical outcomes or logistic regression for categoric outcomes. In all the hypothesis tests the p significant value of \<0.05 were used.

Interventions

DIETARY_SUPPLEMENTInfant Formula

Only Infant Formula without Lactobacillus, Metlin OR Metlos

DIETARY_SUPPLEMENTExclusively breast milk

Children non randomized which mothers decided to feed them with exclusively breast milk

DIETARY_SUPPLEMENTMetlin+metlos+Lactobacillus GG

A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

DIETARY_SUPPLEMENTMetlin + Lactobacillus GG

A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG

DIETARY_SUPPLEMENTMetlos + lactobacillus GG

A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

DIETARY_SUPPLEMENTLactobacillus GG

An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

15 Days to 30 Days

Healthy volunteers

Yes

Inclusion criteria

* Healthy term babies (37 to 42 weeks of gestationl age) * Age 15 ± 7 days at admission * Birth weight \> 2,490 g. * Negative history of formula intolerance (only randomized babies) * Signed Informed Consent

Exclusion criteria

* Clinical evidence of chronic cardiac, respiratory, gastrointestinal, hematological or metabolic disease. * Maternal medical history of diabetes (gestational diabetes was acceptable if the infant's birth weight was at or below the percentile 95; or 4153 g or 9 lbs 3 oz for girls or 4340 g or 9 lbs 9 oz for boys * Tuberculosis, immunologic deficiency, infection disease or perinatal infections known to cause adverse effects in the fetus * Participation in other study * Inability of the father/mother or legal tutor to reed or comprehend the informed consent and the symtoms report diary, or * The infant was part of multiple labor (twins, triplets, etc.)

Design outcomes

Primary

Measure	Time frame	Description
Safety of Metlin & Metlos Aministration in Infant Formula	February 2010 to September 2010	Safety of Metlin & Metlos administration in infant formula was measured by means of the frequency of stools output reported daily by the mother or the keeper (nurse) during the whole study and by the presence gastrointestinal manifestations of intolerance (abdominal distension, flatulency, regurgitations, vomiting), or by the report of eczema type dermatological problems.

Secondary

Measure	Time frame	Description
Efficacy of Administration of Metlin & Metlos in Infant Formula	February 2010 to September 2010	Efficacy of Metlin & Metlos in Infant Formula was measured by means of the change on the intestinal micro flora; changes in the lipids profile (cholesterol, triglycerides, lipoproteins associated to cholesterol); changes in the anthropomorphic profile and somatic growth ( weight gain, stature, arm mean circumference, skin folds); bone mineral metabolism (bone ultrasonography); changes in the immunity (changes in the concentrations of salivary IgA) and reduction of respiratory events suggestive of infection.

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026